AURKA — gene · CancerIndex

Curated evidence

Clinical evidence (8)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
AURKA Amplification1
Alisertib + CisplatinCombination	Esophageal AdenocarcinomaALIAS	Predictive	E	Supports

Cohorts

Alteration frequency by cohort (30)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved30 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Pediatric Pan-cancer (Columbia U, Genome Med 2016) mixed_pipseq_2017	unmapped	Ssm	16	103	15.5%

Literature

Linked publications (6)

25 per page, newest first.

pubmedPublishedShowing 1–6 of 6 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis.
· J Transl Med · 2014 · PMID 25082261 · validated civic_curation pubmed
Aurora kinases as prognostic biomarkers in ovarian carcinoma.
· Hum Pathol · 2009 · PMID 19157502 · validated civic_curation pubmed
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
· J Ovarian Res · 2016 · PMID 27209210 · validated civic_curation pubmed
Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma.
· BMC Cancer · 2015 · PMID 25924824 · validated civic_curation

AURKA EXPRESSION3
(prognostic)	Ovarian Carcinoma	Prognostic	B	Supports Better Outcome	3	accepted	EID416 In patients with ovarian carcinomas, those with Aurora kinase A expression (as measured by immunohistochemistry) had increased progression-free and overall survival compared to those without expressio… (full text at CIViC) PMID 19157502 · Mendiola et al., 2009 · Open in CIViC	civic
Cisplatin + Fluorouracil + Radiation TherapyCombination	Esophageal Squamous Cell CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID1653 A retrospective study examining the expression of AURKA in tumor samples of 78 esophageal squamous cell carcinoma patients found that positive expression of AURKA (>10% of cells by IHC) was correlated… (full text at CIViC) PMID 25924824 · Tamotsu et al., 2015 · Open in CIViC	civic
Tamoxifen	Estrogen Receptor-positive Breast CancerUNRESOLVED	Predictive	D	Supports Resistance	3	rejected	EID1959 Ectopic expression of Aurora-A decreases and depletion of Aurora-A enhances tamoxifen sensitivity in ERα-positive breast cancer. Elevated Aurora-A was significantly associated with the recurrence of E… (full text at CIViC) PMID 24166501 · Zheng et al., 2014 · Open in CIViC	civic

AURKA Overexpression4
Alisertib + CisplatinCombination	Esophageal AdenocarcinomaALIAS	Predictive	D	Supports Sensitivity Response	4	submitted	EID9627 The efficacy of novel AURKA inhibitor alisertib (MLN8327) was tested alone or in combination with cisplatin in three esophageal adenocarcinoma cell lines (FLO-1, OE19 and OE33) that overexpress AURKA.… (full text at CIViC) PMID 22302096 · Sehdev et al., 2012 · Open in CIViC	civic
Cisplatin	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance	4	accepted	EID871 High levels of Aurora-A expression (retrospectively assessed by IHC in 102 NSCLC patients) predicted poorer overall survival and progression free survival in a population treated with surgery and cisp… (full text at CIViC) PMID 25082261 · Xu et al., 2014 · Open in CIViC	civic
Paclitaxel	Cervical AdenocarcinomaCURATED_BROADER	Predictive	D	Supports Resistance	3	accepted	EID457 In the cervial andenocarcinoma cell line HeLa, when AURK-A was overexpressed, the cells were resistant to the apoptotic effects of Taxol. PMID 12559175 · Anand et al., 2003 · Open in CIViC	civic
Platinum Compound	Ovarian Serous AdenocarcinomaALIAS	Predictive	B	Supports Resistance	3	accepted	EID1650 A study of 41 patients with high-grade ovarian serous carcinoma found that high expression levels of AURKA correlated with poorer overall survival (P = 0.001; HR 0.14) and platinum therapy resistance … (full text at CIViC) PMID 27209210 · Mignogna et al., 2016 · Open in CIViC	civic